Two are still open: TRIUMPH-7 (NCT07035093), for obesity or overweight with chronic low back pain, and the Phase 3 multi-agent MASLD master protocol (NCT07165028), which studies several drugs rather than retatrutide alone
For injectable GLP-1 medications: Timing requirements : For once-weekly injections (semaglutide [Ozempic, Wegovy], dulaglutide [Trulicity], exenatide extended-release), administration can occur at any time of day, with or without food
Impulsivity and overeating in children in the absence and presence of hunger
Mislabeling, contamination and dosing error have all been reported
Retail / prestige : sensorial elegance and glow finish justify price
Kidney problems have been reported in some people, particularly with repeated or high-dose treatments